CompletedPhase 1NCT00673010
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Studying Parathyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Ravinder Grewal, MDMemorial Sloan Kettering Cancer Center
- Intervention
- 131 I-iodine (131-I), 124 I-iodine (124-I)(radiation)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2025
Study locations (1)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00673010 on ClinicalTrials.govOther trials for Parathyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06645951Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid AdenomaF.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
- RECRUITINGPHASE2NCT06638931Agnostic Therapy in Rare Solid TumorsInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06835426High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection MarginsAlgemeen Ziekenhuis Maria Middelares
- RECRUITINGNCT04969926Natural History Study of Parathyroid DisordersNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)